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Abstract
Pigs are valuable and essential large animal models for human medical applica-
tions, including for stem cell therapy. Moreover, substantial effort has been made 
to directly engraft genetically engineered pig organs in the human body and to use 
pigs as in vivo bioreactors for the growth and development of human cells, tissue, 
or organs. However, engraftment of human cells in pigs has not yet been achieved. 
Although severe combined immunodeficient pigs have been developed, which can 
accept human biological materials, these pigs do not have practical value at present 
owing to difficulty in their care. To overcome these current limitations, we have 
proposed the generation of operational immunodeficient pig models by simply 
removing the thymus and spleen, enabling the long-term accommodation of human 
tissue. In this review, we summarize research progress on xenotransplantation 
animal models that accept human cells, tissues, or organs.
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1. Introduction
Organ transplantation is often the only possible treatment for a patient with 
organ failure. The organs are donated from either living or deceased donors, and 
thus the number of transplantable organs is limited and insufficient to meet the 
clinical demand. Consequently, some illegal or unethical transplantations along 
with transplant commercialism and tourism have emerged, representing a world-
wide problem.
The discovery of the potential of pluripotent stem cells (PSCs), including 
embryonic stem cells (ESCs) and induced PSCs (iPSCs), to regenerate tissues or 
organs offers new hope to overcome this situation. Human ESCs [1] and iPSCs [2] 
are now widely used to generate tissues or organs, and techniques for the in vitro 
production of specific cell types have been developed [3]. However, these strategies 
still have several limitations for clinical application, including the size, maturity, 
function, and risk of tumor formation after transplantation [4].
To solve these problems, large animal models for the transplantation of human 
PSC-derived cells, tissues, or organs are required. In this review, we summarize 
the animal models currently used in the development for xenotransplantation and 
highlight the efficacy and prospects of pig models to accept human tissues or organs.
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2. Xenotransplantation in small animals (mouse and rat)
Immunosuppression is a key requirement for an animal to accept human tissues 
or organs, as a functional immune system will result in the host animals rejecting 
the human grafts. The nude mouse was the first immunosuppressed animal model 
developed in 1962 [5]. Nude mice lack T cells and can therefore accept human 
tumor cells. Subsequently, severe combined immunodeficient (SCID) mice were 
developed in 1983, which lack both B cells and T cells [6]. McCune et al. [7] suc-
cessfully transplanted a human fetal thymus, liver cells, and lymph node into SCID 
mice, resulting in the differentiation of human T cells and B cells. However, the rate 
of engraftment of human cells in these mice was low due to maintenance of their 
natural killer (NK)-T cell activity. Gerling et al. [8] developed NOD/SCID mice by 
crossbreeding SCID mice with NOD mice, a diabetes model due to autoimmunity 
in the pancreas, which also show low NK-T cell activity and macrophage function 
[9]. Combining the low activity of NK-T cells and macrophages in NOD mice with 
the lack of B cells and T cells in SCID mice, the use of NOD/SCID mice improved 
the engraftment rate of hematopoietic stem cells [10]. Ito et al. [11] produced NOG 
mice as a crossbreed of NOD/SCID mice and gamma(c)(null) mice, which com-
pletely lack NK-T cells, and achieved a dramatically improved engraftment rate of 
human hematopoietic cells.
We previously reported the successful transplantation of rat cells into SCID 
mice [12]. Isolated hepatocytes obtained from the rat liver were injected into 
urokinase-type plasminogen activator (uPA)/SCID mice, in which urokinase-type 
plasminogen accumulates specifically in the native liver causing the damaged 
liver. The mice served as bioreactors to allow the transplanted rat hepatocytes to 
proliferate in the mouse host, resulting in more than 95% of cells in the mouse 
liver being of rat origin. Oldani et al. [13] successfully developed a mouse-rat 
chimeric liver, which was transplanted in rats. They injected hepatocytes isolated 
from Lewis rats into C57Bl/6Fah−/−Rag2−/−Il2rg−/− mice to create chimeric livers, 
which were transplanted into rats with or without immunosuppression. Without 
immunosuppression, the recipient rats died from acute rejection, whereas rats 
with immunosuppression survived for more than 112 days and maturation of rat 
bile ducts was observed 4 months after transplantation. We also demonstrated 
that the nude rat model could serve as an in vivo bioreactor. Liver grafts from 
Syrian hamsters were transplanted into nude rats that administered several immu-
nosuppressive agents, including tacrolimus and mycophenolate mofetil (MMF). 
After auxiliary xenogenic partial liver transplantation, regeneration of the liver 
graft was observed, and its weight increased from pre-transplant to 7 days after 
transplantation [14].
These immunodeficient mouse models, including SCID, NOD/SCID, and NOG 
mice, are useful for research on regenerative medicine using human PSCs, allowing 
for evaluation of teratoma formation to confirm the differentiation of the cells into 
the three germ layers [1]. In addition, these models are widely utilized for evalua-
tion of tumorigenicity in human PSC-derived cells after transplantation [4], since 
human PSC-derived cells or tissues have a risk of tumor formation from contami-
nation of undifferentiated PSCs [15, 16]. Small animals such as mice and rats are 
widely applied as models in cell transplantation research owing to their ease of 
handling. However, small animals have limitations in terms of the number of cells 
that can be transplanted and evaluation of therapeutic efficacy, that is, a human 
clinical application might require the transplantation of several hundreds of million 
cells, which is impossible to accomplish in small animals. Moreover, large animal 
models are required for accurate evaluation of the efficacy of cell transplantation. 
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Furthermore, large animal models are expected to play roles as bioreactors for 
functionally mature human tissues or organs.
3. Xenotransplantation in middle and large animals (monkey and pig)
Chong et al. [17] transplanted human ESC-derived cardiomyocytes into the 
hearts of pig-tailed macaques as a nonhuman primate model. The main advan-
tage of this model is that the hearts are much larger (37–52 g) than those of mice 
(0.15 g), rats (1 g), and guinea pigs (3 g), which allowed for the transplantation 
of 1 × 109 cells into the infarcted myocardium and subsequent engraftment. The 
macaques were administered methylprednisolone, cyclosporine, and abatacept 
(a CTLA4 immunoglobulin) to prevent immune rejection. The efficacy of human 
ESC-derived cardiomyocytes in the infarcted hearts of pig-tailed macaques was 
demonstrated, and maturation of the transplanted ESC-derived cardiomyocytes 
was observed [18]. However, compared to an adult human, pig-tailed macaques 
are still relatively small (5.2–12.6 kg), and the heart is much smaller than that of a 
human (300 g).
Pigs are a suitable animal for preclinical studies and in vivo reactors in terms 
of their size and anatomy that correspond well to those of humans. To establish an 
immunosuppressed state that allows for transplantation of human PSC-derived 
cells or tissues into host pigs without rejection, SCID pigs were also developed [19]. 
Suzuki et al. [19] generated cloned pigs by serial nuclear transfer using fibroblasts 
with disruption of the X-linked interleukin 2 receptor subunit gamma (IL2RG) 
gene, as this mutation is known to cause X-linked SCID in humans. The SCID pigs 
accepted human cells, indicating their potential in preclinical studies and as in vivo 
reactors with human PSCs. However, raising these pigs is a technical challenge; 
among the 31 cloned piglets produced, only four survived for over 1 year. In addi-
tion, SCID pigs must be raised under meticulous hygiene conditions, which impose 
a further cost for their establishment and maintenance. Therefore, it is not practical 
to use SCID pigs as models in preclinical studies and in vivo reactors.
Total thymectomy is an alternative strategy to create immunosuppressed pigs 
that can accept human cells. Binns et al. [20] first proposed the concept of achiev-
ing immunosuppression by performing thymectomy in neonatal pigs in 1972. 
Microminiature pigs (MMPs) are smaller than domestic or ordinary miniature 
pigs and are thus suitable model animals for preclinical studies [21]. To develop 
immunodeficient MMPs, we performed thymectomy in neonatal pigs, which were 
transplanted with human hepatocytes that could engraft in the pig liver without 
any immunosuppressive agents [22]. To further improve the immunodeficient pig 
model, we performed splenectomy along with the thymectomy in 6–7-month-old 
miniature pigs and administered several immunosuppressive agents, including 
tacrolimus, MMF, and prednisolone, via a stomach tube [23]. This so-called opera-
tional immunodeficient miniature pig (OIDP) model allowed for the successful 
implantation of artificial human vascular tubes created by a three-dimensional 
bioprinting. Moreover, the human tube was inserted between the carotid artery and 
jugular vein to act as a shunt, and blood flow was observed for 3 months without 
immune rejection.
As mentioned above, establishment of a chimera is a potential strategy for 
growing human tissues or organs in large animals. Matsunari et al. [24] demon-
strated that blastocyst complementation can be applied to large animals by creat-
ing chimeric pigs. Specifically, they generated embryos from clones of porcine 
somatic cells, which showed an apancreatic phenotype, and their complementation 
Xenotransplantation - Comprehensive Study
4
with allogenic blastomeres resulted in the development of a functional pancreas. 
Wu et al. [25] reported a successful pig-human chimera that was created by 
introducing human PSCs into fertilized pig eggs. Therefore, when combined 
with blastocyst complementation, human organs can be created in a human-pig 
chimera; however, these methods are associated with serious ethical and legal 
problems. Alternatively, the introduction of human-derived cells to pig fetuses 
can lead to immune tolerance, allowing for the acceptance of human PSC-derived 
tissues or organs.
4. Immune tolerance induction for xenotransplantation
Immune tolerance is defined as a lack of an immune response against particular 
antigens. In general, the immune system has tolerance to self-antigens and only 
responds to non-self-antigens, which is a challenge for transplantation, as the 
grafted cells or tissues are rejected and not able to survive in the host body. The 
phenomenon of immune tolerance was first described in 1945 in which anastomosis 
in the placenta was observed in twin calves, and they accepted each other’s skin 
grafts [26]. Hasek et al. [27] subsequently confirmed this phenomenon in chicken 
and duck by producing parabiosis in fertilized eggs. In 1953, Medawar et al. [28] 
established actively acquired tolerance by implanting a live antigen in the fetuses 
of mice or embryonic chicks. Using this method, Binns et al. [29] also tried to 
create immune tolerance in pigs by implanting bone marrow cells or lymphocytes 
from another pig into fetal pigs, resulting in prolonged survival of skin graft in the 
treated pigs.
In addition to these examples, induction of immune tolerance to human cells 
or tissues has been attempted in other animals. Kenneth et al. [30] transplanted 
human mesenchymal stem cells into fetal sheep early in gestation. Despite the 
xenogeneic condition, the human mesenchymal stem cells engrafted and survived 
in multiple tissues for up to 13 months after transplantation. These strategies of 
injecting human cells into a fetus were proven to result in immune tolerance to 
human cells after birth.
As MMPs have emerged as suitable candidates for immune tolerance induc-
tion to accept human cells, tissues, and organs owing to their useful applications 
in preclinical studies and in vivo reactors, it may be possible to create MMPs with 
immune tolerance to human cells by injecting a human antigen into pig fetuses 
without requiring the need to create human-pig chimeras [31].
5. Conclusions
Our newly developed OIDPs can accept human cells, tissues, and organs derived 
from human PSCs. These models will allow for long-term observation after the 
transplantation of human PSC-derived cells or tissues to better evaluate the safety 
and efficacy of the procedure. Moreover, if human cells, tissues, and organs are 
transplanted into piglets, they will grow in vivo along with the growth of the host 
pig. These grafts will then mature and be of suitable size with appropriate function 
for human application. Therefore, pigs can be suitable models for preclinical studies 
and serve as in vivo bioreactors for developing human tissues or organs (Figure 1). 
Transplantable MMPs without immunosuppressive agents are expected to be 
developed in the near future as promising and valuable animal models for research-
ers, which can dramatically promote regenerative medicine and organ transplant 
therapies with human PSCs.
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Figure 1. 
Schema of pigs as models of preclinical studies and in vivo bioreactors. (A) Adult operational immunodeficient 
miniature pigs (OIDPs) are useful for preclinical studies in regenerative medicine with human PSCs, enabling 
evaluation of the safety and efficacy of cell transplantation. In particular, after transplantation of human 
PSC-derived spheroids or organoids into the OIDPs, the risk of tumorigenicity can be evaluated. (B) Fetal 
or neonatal OIDPs are also useful as in vivo bioreactors, facilitating the efficient in vivo growth of immature 
human tissues. After immature human PSC-derived tissues or organs are transplanted into OIDPs, they will 
mature along with the growth of the host.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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